Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios/Virginio) are creating new dynamics in the metastatic HR-positive/HER2-negative treatment practice. In HER2-positive breast cancer, emerging HER2-targeting drugs in development are forecast to enter the market, while current HER2-targeting agents will see their sales change as a result of competition, label expansions, biosimilars entry, and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Talzenna), PD-1-targeting agents (Roche/Genentech/Chugai’s Tecentriq), and PI3K inhibitors (Novartis’s Piqray), as well as anticipated entry of agents within these drug classes will provide more diverse and much needed treatment options, especially for triple-negative breast cancer.

Questions answered

  • What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as the CDK4/6 inhibitors, immune checkpoint inhibitors, PARP  inhibitors, and PI3K inhibitors in the various subpopulations of breast cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
  • What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?

Contents Highlights

Geographies: United States, EU5, Japan

Primary Research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research

Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy

Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2028, segmented by brands/generics and market-relevant drug-treatable populations

 Emerging Therapies: Phase III/PR: 15 drugs; coverage of select Phase I and II products

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Related Reports

Breast Cancer | Landscape & Forecast | Disease Landscape & Forecast

Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4

View Details

Breast Cancer | Geographic Focus - China | Breast Cancer | China In-Depth | China

COMING SOON Breast cancer is one of the most frequently diagnosed cancers among Chinese women. A high incidence and a prolonged treatment duration makes breast cancer a...

View Details

Breast Cancer | Unmet Need | Detailed, Expanded Analysis: Advanced/Metastatic Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment...

View Details

Breast Cancer | Access & Reimbursement | Detailed, Expanded Analysis - Optimizing Market Access Amid an Evolving Landscape for HR+/HER2- Therapies (EU)

MARKET OUTLOOK The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novar...

View Details